Abivax S.A.
NASDAQ:ABVXBiotechnology
-$0.62 today
- Market cap
- $7.34B
- Beta
- -0.20
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$4.83
Volume 1.19M
Average 1.59M
ABVX Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Abivax S.A.NASDAQ: ABVX
Free Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Free cash flow grows 56.2% year over year
Q2 FY2026 free cash flow of €52.1M (cash outflow) rose 56.2% year over year. Over 3 fiscal years it compounded at +42.1% a year.
Context
- Free cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
EUR · from the cash flow
- Latest · FY2025
- (155.83M) EUR
- Year-over-year change
- -0.7%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (155.83M) | -0.7% |
| FY2024 | 2024-12-31 | (154.72M) | -54.3% |
| FY2023 | 2023-12-31 | (100.28M) | -84.8% |
| FY2022 | 2022-12-31 | (54.26M) | -20.3% |
| FY2021 | 2021-12-31 | (45.1M) | — |
Free Cash Flow vs competitors
How ABVX compares with its peers on the latest reported figures
- Peers report in different currencies, so free cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +0.7% is the 10th highest of 11, against a peer median of +34.9%.
- Over three fiscal years its annual growth of +42.1% compares with a peer median of +26.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $475M USD | +38.9% | — | 406.0% | |
| LTM Aug 2026 | $369.81M USD | +253.2% | +15.3% | 52.7% | |
| LTM Mar 2026 | $278.35M USD | -2.9% | +34.1% | 128.2% | |
| LTM Sep 2026 | $249.32M USD | +54.0% | +28.3% | 275.5% | |
| LTM Mar 2026 | $183.16M USD | +30.9% | +14.9% | — | |
| FY2025 | €155.83M EUR | +0.7% | +42.1% | — | |
| FY2025 | €101.22M EUR | +17.3% | +30.6% | 2257.9% | |
| LTM Mar 2026 | $59.69M USD | +14.1% | +24.2% | 101172.9% | |
| LTM Mar 2026 | $52.27M USD | +8.5% | -11.6% | 624.8% | |
| LTM Mar 2026 | $32.77M USD | +144.6% | +49.3% | — | |
| LTM Mar 2026 | $4.41M USD | +104.0% | — | 1.9% | |
| Peer median (excluding ABVX) | — | +34.9% | +26.2% | 340.7% | |
Competitors are the stored peer set for ABVX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (42.45M) | (60.74M) | (147.74M) | (176.24M) | (322.84M) |
| Depreciation & Amortization | 302K | 485K | 707K | 1.1M | 1.07M |
| Deferred Income Tax | 0 | 0 | 7.93M | 0 | 0 |
| Stock-Based Compensation | 828K | (1.16M) | 8.18M | 20.22M | 0 |
| Change in Working Capital | (668K) | (2M) | 21.27M | 1.42M | 3.51M |
| Accounts Receivables | (1.98M) | 312K | (14.23M) | 4.59M | 6.76M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.14M | (2.39M) | 31.76M | (3.44M) | 0 |
| Other Working Capital | 168K | 74K | 3.74M | 276K | (3.26M) |
| Other Non-Cash Items | (3.06M) | 9.49M | 9.65M | (577K) | 162.57M |
| Operating Cash Flow | (45.05M) | (53.94M) | (100.01M) | (154.07M) | (155.69M) |
| Capital Expenditures | (47K) | (323K) | (265K) | (643K) | (136.4K) |
| Acquisitions (Net) | (2.18M) | (2.91M) | 0 | 0 | 0 |
| Purchases of Investments | (9K) | (470K) | (9.35M) | 0 | (13.59M) |
| Sales of Investments | 0 | 218K | 741K | 0 | 480.27K |
| Other Investing Activities | (4M) | (8.57M) | (1.62M) | 16.4M | 68.2K |
| Investing Cash Flow | (6.23M) | (12.03M) | (10.5M) | 15.76M | (13.18M) |
| Debt Repayment | 19.13M | (9.71M) | 15.24M | 37.49M | (56.31M) |
| Common Stock Issued | 69.68M | 46.37M | 353.39M | 434K | 588.84M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (6.13M) | (4.45M) | (28.06M) | (9.71M) | (586.89K) |
| Financing Cash Flow | 82.68M | 32.21M | 340.57M | 28.21M | 531.94M |
| Effect of Forex Changes | 0 | 0 | (5.07M) | 2.38M | 26.29M |
| Net Change in Cash | 31.4M | (33.75M) | 224.99M | (107.72M) | 389.36M |
| Free Cash Flow | (45.1M) | (54.26M) | (100.28M) | (154.72M) | (155.83M) |
Abivax S.A.
NASDAQ:ABVX
Intrinsic Alpha fair value
Locked
Current Price
$83.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.